Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Mind Medicine Mindmed Inc (MNMD)

Mind Medicine Mindmed Inc (MNMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
MindMed Announces New Employee Inducement Grant Business Wire - Mon Dec 15, 3:01PM CST

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 12.08 (-3.75%)
MindMed Announces New Employee Inducement Grants Business Wire - Mon Dec 1, 3:01PM CST

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 12.08 (-3.75%)
MindMed Reports Q3 2025 Financial Results and Business Updates Business Wire - Thu Nov 6, 3:01PM CST

-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)-- ...

MNMD : 12.08 (-3.75%)
MindMed to Participate in Upcoming Investor Conferences Business Wire - Wed Nov 5, 6:01AM CST

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 12.08 (-3.75%)
MindMed Announces New Employee Inducement Grant Business Wire - Mon Nov 3, 3:01PM CST

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 12.08 (-3.75%)
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares Business Wire - Mon Nov 3, 6:01AM CST

Mind Medicine (MindMed) Inc . (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MNMD : 12.08 (-3.75%)
MindMed to Report Q3 2025 Financial Results on November 6, 2025 Business Wire - Thu Oct 30, 3:01PM CDT

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 12.08 (-3.75%)
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering Business Wire - Wed Oct 29, 9:14PM CDT

Mind Medicine (MindMed) Inc . (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MNMD : 12.08 (-3.75%)
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering Business Wire - Wed Oct 29, 3:01PM CDT

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MNMD : 12.08 (-3.75%)
MindMed Issues Inducement Grant to New Employee Tipranks - Thu Oct 16, 3:46PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

MNMD : 12.08 (-3.75%)

Barchart Exclusives

This Dividend ETF Has Crushed the S&P 500 in 2025. Should You Buy It Before 2026? Barchart - Mon Dec 15, 6:30PM CST
After trouncing the S&P 500 this year, FDD looks best approached gradually or on pullbacks, since most of the easy upside is likely behind it and future returns will probably come from steadier dividends and slower price appreciation rather than another explosive rally. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot